Nadia Withofs1, Nicolas Signolle2, Joan Somja3, Pierre Lovinfosse4, Eugène Mutijima Nzaramba3, Frédéric Mievis5, Fabrice Giacomelli5, David Waltregny6, Didier Cataldo2, Sanjiv S Gambhir7, Roland Hustinx4. 1. Nuclear Medicine and Oncological Imaging Division, Medical Physics Department, CHU Liege, Liege, Belgium nwithofs@chu.ulg.ac.be. 2. Laboratory of Tumor and Developmental Biology, GIGA Research, University of Liege, Liege, Belgium. 3. Pathology Department, CHU Liege, Liege, Belgium. 4. Nuclear Medicine and Oncological Imaging Division, Medical Physics Department, CHU Liege, Liege, Belgium. 5. Cyclotron Research Center, University of Liege, Liege, Belgium. 6. Urology Department, CHU Liege, Liege, Belgium; and. 7. Molecular Imaging Program at Stanford (MIPS), Radiology Department, Stanford University, Stanford, California.
Abstract
UNLABELLED: This study aimed to correlate (18)F-FB-mini-PEG-E[c(RGDyK)](2) ((18)F-FPRGD2) uptake to integrin αvβ3 expression and angiogenesis in renal tumors. METHODS: (18)F-FPRGD2 PET/CT was performed on 27 patients before surgical resection (median 4 d) of a renal mass. The (18)F-FPRGD2 uptake was compared with integrin αvβ3, CD31, CD105, and Ki-67 using immunohistochemistry; with placental growth factor and vascular endothelial growth factor receptors 1 and 2 using reverse transcription polymerase chain reaction; and with vascular endothelial growth factor A isoforms using enzyme-linked immunosorbent assay. RESULTS: Overall, (18)F-FPRGD2 uptake significantly correlated (P < 0.0001) with integrin αvβ3 expression in renal masses. However, it correlated only with integrin αvβ3-positive vessels in the group of papillary carcinomas whereas it correlated with integrin αvβ3 expression by tumor cells in the clear cell carcinoma group. CONCLUSION: (18)F-FPRGD2 uptake reflects the expression of integrin αvβ3 in renal tumors but represents angiogenesis only when tumor cells do not express the integrin.
UNLABELLED: This study aimed to correlate (18)F-FB-mini-PEG-E[c(RGDyK)](2) ((18)F-FPRGD2) uptake to integrin αvβ3 expression and angiogenesis in renal tumors. METHODS: (18)F-FPRGD2 PET/CT was performed on 27 patients before surgical resection (median 4 d) of a renal mass. The (18)F-FPRGD2 uptake was compared with integrin αvβ3, CD31, CD105, and Ki-67 using immunohistochemistry; with placental growth factor and vascular endothelial growth factor receptors 1 and 2 using reverse transcription polymerase chain reaction; and with vascular endothelial growth factor A isoforms using enzyme-linked immunosorbent assay. RESULTS: Overall, (18)F-FPRGD2 uptake significantly correlated (P < 0.0001) with integrin αvβ3 expression in renal masses. However, it correlated only with integrin αvβ3-positive vessels in the group of papillary carcinomas whereas it correlated with integrin αvβ3 expression by tumor cells in the clear cell carcinoma group. CONCLUSION: (18)F-FPRGD2 uptake reflects the expression of integrin αvβ3 in renal tumors but represents angiogenesis only when tumor cells do not express the integrin.
Authors: Philipp M Kazmierczak; Andrei Todica; Franz-Josef Gildehaus; Heidrun Hirner-Eppeneder; Matthias Brendel; Ralf S Eschbach; Magdalena Hellmann; Konstantin Nikolaou; Maximilian F Reiser; Hans-Jürgen Wester; Saskia Kropf; Axel Rominger; Clemens C Cyran Journal: PLoS One Date: 2016-12-19 Impact factor: 3.240
Authors: Jamila Hedhli; Andrzej Czerwinski; Matthew Schuelke; Agata Płoska; Paweł Sowinski; Lukas La Hood; Spencer B Mamer; John A Cole; Paulina Czaplewska; Maciej Banach; Iwona T Dobrucki; Leszek Kalinowski; Princess Imoukhuede; Lawrence W Dobrucki Journal: Sci Rep Date: 2017-06-09 Impact factor: 4.379
Authors: Nadia Withofs; François Cousin; Bernard De Prijck; Christophe Bonnet; Roland Hustinx; Sanjiv S Gambhir; Yves Beguin; Jo Caers Journal: Contrast Media Mol Imaging Date: 2017-07-27 Impact factor: 3.161
Authors: Giulia Marelli; Roberta Avigni; Paola Allavena; Cecilia Garlanda; Alberto Mantovani; Andrea Doni; Marco Erreni Journal: Oncotarget Date: 2018-07-31